Ikena Oncology, Inc. (IKNA)
NASDAQ: IKNA · IEX Real-Time Price · USD
1.630
-0.020 (-1.21%)
At close: Jul 2, 2024, 4:00 PM
1.639
+0.009 (0.55%)
After-hours: Jul 2, 2024, 5:38 PM EDT
Ikena Oncology Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Ikena Oncology stock have an average target of 3.00, with a low estimate of 2.00 and a high estimate of 4.00. The average target predicts an increase of 84.05% from the current stock price of 1.63.
Analyst Consensus: Buy
* Price targets were last updated on May 29, 2024.
Analyst Ratings
The average analyst rating for Ikena Oncology stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 1 | 1 | 1 | 1 |
| Buy | 2 | 2 | 2 | 2 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 3 | 3 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy → Hold Downgrades $8 → $2 | Buy → Hold | Downgrades | $8 → $2 | +22.70% | May 29, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $11 → $4 | Strong Buy | Maintains | $11 → $4 | +145.40% | May 29, 2024 |
| Wedbush | Wedbush | Buy Reiterates $8 | Buy | Reiterates | $8 | +390.80% | May 14, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +574.85% | Mar 19, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $11 | Strong Buy | Maintains | $11 | +574.85% | Mar 12, 2024 |
Financial Forecast
Revenue This Year
3.57M
from 9.16M
Decreased by -61.03%
Revenue Next Year
3.57M
from 3.57M
EPS This Year
-1.29
from -1.63
EPS Next Year
-1.07
from -1.29
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 14.7M | 14.7M | 14.7M | 29.4M | 73.5M |
| Avg | 3.6M | 3.6M | 3.6M | 10.7M | 42.8M |
| Low | n/a | n/a | n/a | n/a | 13.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 60.5% | 311.8% | 311.8% | 723.5% | 586.3% |
| Avg | -61.0% | - | - | 200.0% | 300.0% |
| Low | - | - | - | - | 28.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.93 | -0.64 | -0.54 | -0.81 | -0.42 |
| Avg | -1.29 | -1.07 | -0.88 | -1.00 | -0.83 |
| Low | -1.52 | -1.44 | -1.06 | -1.25 | -1.20 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.